Table 4 Baseline characteristics of patients with complete or partial responses per mRANO criteria
From: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
2401013 | 2401039 | 2401045 | 2401047 | 2401019 | |
|---|---|---|---|---|---|
Response to treatment | CR | PR | CR | PR | PR |
Maximum reduction in tumor volume from baseline | 100 | 72.2 | 100 | 63.6 | 78.1 |
PFS, months | 41.6a | 5.3 | 26.8a | 3.7 | 26.9 |
Survival, months | 41.6 (alive) | 21.5 | 26.8 (alive) | 15.4 | 29.7 (alive) |
Age, years | 26 | 50 | 27 | 39 | 51 |
Recurrences, no. | 1 | 1 | 2 | 1 | 2 |
Prior resection | No | Total resection | Total resection | No | No |
Baseline steroids | Yes | Yes | No | No | No |
IDH1 R132H mutation status (IHC) | Wild typeb | Wild type | Wild type | Wild type | Wild typec |
MGMT promoter methylation status | Unknown | Unmethylated | Methylated | Unknown | Methylated |
Maximal tumor diameter (mm) | 40.4 | 32.8 | 38 | 19 | 28 |
Pretreatment PD-L1 expression by IHC | Unknown | Negative | Unknown | Negative | Positive |
Tumor mutational burden (nonsynonymous mutations per 10 megabases) | 5.7 | 7.8 | 10.0 | 7.8 | 10.0 |
